Prospective evaluation of WHO and European clinical, molecular and pathological (WHO-ECMP) criteria for myeloproliferative neoplasms (MPN) of various molecular etilogiy: characterisitcs of JAK2 V617F, MPL 515 and CALR mutated MPN by Michiels, JJ et al.
Annex Publishers | www.annexpublishers.com                    
 
Volume 1 | Issue 1
Abstract
The WHO defined JAK2V617F mutated myeloproliferative neoplasms (MPN) consist of normocellular essential thrombocythemia (ET), 
ET with features of early PV (prodromal PV), ET with hypercelular megakaryocytic granulocytic myeloproliferation (ET.MGM), and 
various stages of polycythemia vera (PV) when the WHO and European Clinical and Pathological (WHO-ECMP) criteria are applied. 
Bone marrow cellularities on histopathology are overlapping in normocellular ET, prodromal PV and PV carrying the JAK2V617F 
mutation. Increased erythrocyte counts at a cut off level of 5.8x1012/L separates JAK2 mutated ET and prodromal PV from overt PV. 
JAK2 wild type ET and MF carrying the MPL515 mutation is a distinct MPN entity featured by increase of clustered small and giant 
megakaryocytes with hyperlobulated stag-horn-like nuclei, in a normal cellular bone marrow without features of PV. JAK2/MPL wild 
type ET and MF carrying one of the calreticulin (CALR) mutations is the third distinct entity associated with prefibrotic primary 
megakaryocytic and granulocytic myeloproliferation (PMGM) characterized by dense clustered, large, and immature dysmorphic 
megakaryocytes with bulky (bulbous) hyperchromatic nuclei, which are never seen in JAK2V617F mutated ET, prodromal PV, EMGM 
and PV, and also not in MPL515 mutated ET and MF.  
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As the PVSG classification provided no strict definitions for early stage essential thrombocythemia (ET) and polycythemia vera 
(PV), we defined in 1980 the Rotterdam Clinical and Pathological Criteria (RCP) for the diagnosis of ET and PV (Table 1) [1]. 
Michiels & Thiele improved the RCP criteria for ET and PV and defined the European Clinical and Pathologic (ECP http://www.
mpn-stichting.nl/doctors_brochure_2004.pdf) for ET, PV and hypercellular ET with features of prefibrotic myelofibrosis (MF) 
[2-8]. Thiele joined the WHO to define the 2008 WHO classification of the myeloproliferative neoplasms (MPN) ET, PV and 
primary myelofibrosis (PMF) [9,10]. In response to the significant shortcomings of the 2008 WHO classification, we could much 
better define the WHO and European Clinical Molecular and Pathological (WHO-ECMP) [11-13] criteria by the combined use 
of bone marrow histology, biological laboratory markers and JAK2V617F mutation screening to distinguish the broad spectrum 
of JAK2V617F mutated trilinear MPN entity (Tables 2 and 3) to clearly separate JAK2 mutated MPN from JAK2 wild type MPN 
carrying one of the MPL or calreticulin (CALR) mutations (Tables 4 and 5) [14,15]. The 2008 WHO defined prefibrotic JAK2V617F 
mutated myeloproliferative neoplasms (MPN) can be subclassified and staged as normocellular essential thrombocythemia (ET), 
ET with features of early PV (prodromal PV), ET with hypercelular megakaryocytic granulocytic myeloproliferation (ET.MGM), 
and various stages of polycythemia vera (PV) when the WHO-ECMP criteria are applied (Tables 2 and 3). In this report we could 
Received Date: June 26, 2015 Accepted Date: August 03, 2015 Published Date: August 05, 2015
Volume 1 | Issue 1
Journal of Hematology and  Blood Disorders
ISSN: 2455-7641
Annex Publishers | www.annexpublishers.com                    
 
Volume 1 | Issue 1
 
2Journal of Hematology and  Blood Disorders
distinguish JAK2V617F positive ET and prodromal PV from JAK2/wild type normocellular ET carrying the MPL515 as a distinct 
MPN entity with no features of PV. JAK2/MPL wild type CALR mutated hypercellular ET is associated with prefibrotic primary 
megakaryocytic granulocytic myeloproliferation (PMGM) and appears to be the third MPN entity of ET and MF without features 
of PV. 
        A. The 1980 RCP major (A) and confirmative (B) criteria for prefibrotic ET [1]
Persistent platelet count in excess of 400x109/L.A1
Increase and clustering of enlarged megakaryocytes in bone marrow biopsy.A2
No or slight increase of reticulin fibers (RF 0 or RF 1)A3
Presence of large platelets in a peripheral blood smearB1
Absence of any underlying disease for reactive thrombocytosis and normal ESR.B2
No or slight splenomegaly on palpation or scan (<15 cm)B3
Increase of LAP-score and no signs of fever or inflammationB4
       Exclusion criterion
       Ph+ chromosome and any other cytogenetic abnormality in blood or bone marrow cells 
Table 1: The 1980 Rotterdam Clinical and Pathological (RCP) criteria for Essential Thrombocythemia (ET) and Polycythemia 
Vera (PV)[1]
        B. The 1980 RCP major (A) and minor (B) criteria for prefibrotic PV [1]
Raised red cell mass. Male >36 ml/kg, female >32 ml/kg consistent with erythrocyte 
count of >6x1012/L (Dameshek 1940 [18])A1
Absence of primary or secondary erythrocytosis by clinical and laboratory tests.A2
Slight, moderate or marked increase in bone marrow biopsy of clustered, enlarged 
pleomorphic megakaryocytes with hyperlobulated nuclei and moderate to marked 
increase cellularity of megakaryopoiesis/erythropoiesis or typically trilinear mega-
erythro-granulopoiesis.
A3
Thrombocythemia, persistant increase of platelet >400x109/LB1
Leukocytosis, leucocyte count >109/L and low erythrocyte sedimentation rate (ESR)B2
Raised leukocyte alkaline phosphatase (LAP) score >100, absence of fever or infectionB3
Splenomegaly on palpation or on isotope/ultrasound scanningB4
       A1+ A3 plus one of B establishes PV and excludes any variant of erythrocytosis
C. Grading of bone marrow reticulin fibrosis (RF) and grading of myelofibrosis (MF)[5-8]
Description of reticulin fibers (RF) and reticulin/collagen fibers (RCF)in myelofi-
brosis (MF) [22] as a secondary event in myeloproliferative neoplasms (MPN)
Grading MF 
Thiele, et al.
Grading reticulin
fibrosis (RF) 
 No reticulin fibers, occasional individual fibers or focal areas with tiny amount of 
reticulin fiber network
N
MF 0
Normal
RF-0
Fine reticulin fiber network throughout much of section and no course reticulin 
fibers
 +
MF 0
Slight increase
RF 1
Diffuse fine reticuline network with focal collections of thick course reticulin   
fibers and no collagenisation
+ +
MF 1 
Moderate increase 
RF 2
Diffuse and dense increase in reticulin with extensive intersections, and presence 
of collagen fibers and no or minor osteosclerosis
+++
RCF = MF 2
Marked increase 
BM dry tap RF 3 
Diffuse and dense reticulin with coarse bundles of collagen associated with 
significant osteosclerosis (O)
Sclerotic
RCF&O = MF 3
OS Dry tap 
RF 4
Bone marrow pathology criteria (WHO)Clinical and molecular criteria
Normocellular ETET
Predominant proliferation of enlargedmature megakaryocytes with hyperlobulat-
ed nuclei and mature cytoplasm, lacking conspicuous morphological abnormali-
ties. No increase, proliferation or immaturity of granulopoiesis or erythropoiesis. 
Reticuline fibrosis (RF) 0 or 1 
1. Platelet count of >350 x109/l and the presence of large                                         
platelets in a blood smear
2. Presence of JAK2-V617 F mutation 
3. Normal erythrocytes, haemoglobin (Hb) and hematocrit (ht) 
ET with features of PV                        Prodromal PV
Increased cellularity with due to increased erythropoiesis or trilineage myelo-
proliferation (i.e. panmyelosis). Proliferation and clustering of small to giant 
(pleomorphic) megakaryocytes.
Absence bone marrow features consistent with congenital polycythemia and 
secondary erythrocytosis. RF 0 or 1 
1. Platelet count of > 350 x109/l and normal ht male <0.51, 
female <0.48, normal erythrocyte <5.8x1012/L is mandatory.
2. Presence of JAK2-V617F mutation 
3. Low serum EPO level and/or increased LAP score 
4. Spontaneous EEC.
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Table 2: WHO and European clinical molecular pathological (WHO - ECMP) criteria for diagnosis and classification of 
prefibrotic JAK2V617F mutated prefibrotic ET [15,25]
Table 4: 2014 WHO Clinical Molecular and Pathological (2014 WHO-CMP) criteria for the diagnosis of normocelular 
ET carrying one of the MPL515 mutations [15,25]. This entity is identical to ‘true’ ET as defined in 2002 by Michiels & 
Thiele [5].
Bone marrow pathology criteria (WHO)Clinical and molecular criteria
                                        ET.MGM           Prefibrotic hypercellular ET
Hypercellular ET due to chronic megakaryocytic and granulocytic myeloprolif-
eration (ET.MGM) and normal or reduced erythroid precursors.
Loose to dense clustering of more pleiomorphic megakaryocytes with hyperploid 
or clumpsy nuclei (not or some cloud-like).
Prefibrotic: RF- 0/1, MF-0, no/minor splenomegaly 
--------------------------------------------------------
Early fibrotic ET:RF 2, MF 1, splenomegaly no/minor
Fibrotic ET : RF3, RCF or MF2, overt splenomegaly
------------------------------------------------------------
Post-ET MF: RF3/4, or MF-2/3 (2008 WHO PMF)
1. Platelet count of >350 x109/l,
2. No signs of leuko-erythroblastosis
3. Slight or moderate splenomegaly on ultrasound 
4. No anemia with hb and ht in the normal low normal range: 
hb>13g/dl
5. Presence of JAK2-V617 F mutation 
6. No preceding or allied CML, PV, RARS-T or MDS.
------------------------------------------------- 
ET stage 4, borderline anemia and LDH↑
ET stage 5 Hb<12 g/dL, LDH↑↑, CD34+
------------------------------------------------- 
ET stage 6, Post-ET MF (2008 WHO)
Bone marrow pathology criteria (WHO)Clinical and molecular criteria
PV. Bone marrow pathology: increased cellularity (60-100%) due to trilinearin-
crease of erythropoiesis, megakaryopoiesis and granulopoiesis and clustering of 
small to giant (pleomorph) megakaryocytes with hyperlobulated nuclei.
Absence of stainable iron. No pronounced inflammatory reaction (plasmacytosis, 
cellular debris)
Erythrocytosis. Increase of erythropoiesis, normal granulopoiesis and mega-
karyocytes of normal size, morphology and no clustering in primary/secondary 
erythrocytosis.
Grading of reticulin fibrosis (RF) and myelofibrosis (MF) 
Erythrocythemic stage: A1 and P1
Prefibrotic: RF-0/1 = MF-0
Early fibrotic: RF-2 = MF-1
Fibrotic: RCF 3 = MF-2
Post-PV MF: RF 4 = MF-3
Major
Prodromal PV (ET stage 2). Hematocrit upper limit of normal: 
Ht: 0.45 to 0.51 in male and 0.43 to 0.48 in female), erythrocytes 
<5.8x1012/L
PV
A1. Hematocrit >0.51/>0.48 in male/female, erythrocytes 
>5.8x1012/L 
A2. Presence of heterozygous or homozygous JAK2V617F or JAK2 
exon 12 mutation
A3. Low serum Epo level 
Minor
B1. Persistent increase of platelet count: grade I: 400-1500, 
grade II: >1500 x109/L
B2. Granulocytes >10 x109/l or Leukocytes >12 x109/l and/or 
raised LAP-score in the absence of fever or infection
B3. Splenomegaly on palpation or on ultrasound echogram 
(>12 cm length in diameter).
B4. Spontaneous endogenous erythroid colony (EEC) forma-
tion (optional)
On top of WHO bone marrow histology: ECMP criteria for staging of early, overt, and advanced PV
A0, A2, B1 establish early PV (mimicking ET) PV ECMP stage 0, or masked PV
A1, A2, and none of B establish polycythemic PV ECMP stage 1
A1, A2, and one or more of B establish classic and advanced PV ECMP stage 2 and 3
A2, B3 and P1 detect masked ET or PV: primary myeloproliferative disease (PMD) 
A3 and B4, bone marrow smear and JAK2V617F mutation is an important research option.
Table 3: WHO-ECMP criteria for the diagnosis of PV and erythrocytoses [15,25]
Bone marrow pathology (P) criteria (WHO)Clinical and molecular (CM) JAK2 wild type ET
P1. Proliferation of large to giant mature megakaryo-
cyte with hyperlobulated, staghorn-like nuclei in a 
normocellular bone marrow (<65%)
No increase of erythropoiesis, and no increase or 
immaturity of granulopoiesis or erythropoiesis, No or 
slight increase in reticulin RF 0/1
ET → MF
Increased reticulin fibrosis around dense clustered 
megakaryocytes in a normocellular bone marrow and 
reduced erythropoiesis. Follow-up data of RF and 
MF related to splenomegaly in MPL515 ET transltional 
states to MF are lacking. Grading of reticulin fibrosis 
(RF) and myelofibrosis (MF) is similar as described 
for PV
1. Platelet count >350x109/L and presence of large platelets in 
blood smear
2. Hemoglobin, haematocrit and erythrocyte count in the 
normal range
3. Presence of MPL515 mutation and JAK2 wild type
4. Normal serum EPO
5. Normal LAP score and CD11b expression
6. No or slight splenomegaly
7. No leukoerythroblastosis
8. No preceding or allied CML, PV, RAS-T or MDS
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Pathological ECP criteria of CALR MGMClinical (CM) criteria JAK2 wild type PMGM
P1  Primary megakaryocytic granulocytic myeloproliferation (PMGM) and 
relative or absolute reduction of erythropoiesis and erythroid precursors. Ab-
normal dense clustering and increase in atypical medium sized, large to giant 
immature megakaryocytes containing bulbous (cloud-like) hypolobulated 
nuclei and definitive maturation defects
MF  Grading reticulin fibrosis (RF), myelofibrosis (MF) 
MF0 Prefibrotic CALR MGM, no reticulin fibrosis RF 0/1
MF1 Early fibrotic CALR MGM slight reticulin fibrosis RF2
MF2 Fibrotic CALR MGM increase RF grade 3 and slight to moderate col-
lagen fibrosis
MF3 Advanced fibrotic CALR MGM with collagen fibrosis-osteosclerosis
A1  No preceding or allied other subtype of myeloproliferative neoplasm PV, 
CML, MDS. The main presenting features is pronounced isolated thrombo-
cythemia with platelet count around or above 1000x109/L
A2  Presence of CALR mutation and JAK2 wild type 
C  Clinical stages of CALR MGM
C1. Early clinical stage: Hb>12g/dL, slight to moderate splenomegaly, throm-
bocytosis around or above 1000x109/L, normal LAP score
C2. Intermediate clinical stage: slight anemia Hb<12 to >10 g/dL, decreas-
ing platelet count, splenomegaly, increased LDH and definitive tear drop 
erythrocytes
C3. Advanced stage: anemia Hb<10g/dL, tear drop erythrocytes, increased 
LDH, increased CD34+ cells, pronounced splenomegaly, normal or de-
creased platelet counts, leucocytosis or leukopenia.
The combination of A1 + A2 and P1 establishes CALR ET and various clinical stages (C1, C2,C3) related to the degree of myelofibosis (MF)
Table 5: 2016 WHO-CMP criteria for hypercellular ET associated with primary megakaryocytic, granulocytic myeloproliferation (PMGM) caused by 
calreticulin (CALR) mutations [15,25]. This entity has been defined as PMGM in the 1990 Bone Marrow Classification by Georgii, et al. [22] as the third 
distinct MPD entity.
Methods 
Hemoglobin, hematocrit, erythrocytes, leukocytes, platelets, iron status and chemical parameters were routinely performed. 
Erythrocyte volume (red cell mass RCM) was measured using Cr51 (natriumchromate) labeled autologous erythrocyte and plasma 
volume was measures with J131-human serum albumin. The leukocyte-alkaline-phosphatase (LAP) stain was performed with Na-
naphtyl and Fast Garnet G.B.C Salt. Iron stain of bone marrow smears were performed with Prussian blue reagens. Bone marrow 
biopsies from the iliac crest were stained with hematoxylin and eosin for histopathology evaluation. All bone marrow biopsies were 
evaluated by expert hematopathologists for morphology, grading of cellularity and scoring of reticulin fibers according to PVSG 
recommendations [16] (Table 1). Our pathologists used the collagen staining of Mason for objective detection of collagenisation 
of reticulin fibers to clearly distinguish between early stage reticulin fibrosis (RF) from advanced reticulin/collagen fibrosis for 
grading of myelofibrosis (MF, Table 1C).
Results period 1975→1985
Results 
In the period of January 1975 to December 31, 1980, we prospectively studied 30 consecutive early prefibrotic stage MPD patients, 
who presented with erythromelalgic thrombotic thrombocythemia (ETT), 14 ET and 16 PV patients (Table 6). The mean age of 
30 ETT patients (ET and PV) was 56.7 (range 33-96) years. Eleven of 14 ET patients had platelet counts below 1000x109/L. Spleen 
size on scan was slightly increased in 5 of 14 ET and in 13 of 16 PV patients. Leukocyte count counts was increased (>10x109/L) in 
5 out of 14 patients with ET and in 14 of 16 PV patients. LAP score was increased (>100) in 12 out of 14 ET and in all PV patients. 
ErythrocHtHbPlateletsBMBMBMEry/PlasmLAFLeukocNumber
1012 /Lmmol/l109/LcellularitymegakarRFvolumescore109/L
6.70.4910.4792N1+N31 / 4118310A1 ETPV
6.00.5110.0887N1+N1559A2 ETPV
5.40.478.99112+2+1+1098A3 ET
4.50.398.06141+1019A4 ET
4.40.408.3939N1+N26 / 3712816A5 ET
5.80.499.8742N1+N1397A6 ET
5.20.469.5567N1+N1278A7 ET
4.90.438.88751+2+1+3810A8 ET
5.50.458.86901+1+1+10310A9 ET
4.70.438.61440N1+N6011A10 ET
6.10.469.414351+2+2+32 / 4311313A11 ETPV
6.50.5611.119322+1+1+59 / 5220710A12 PV
7.60.6212.118002+2+N19328A13 PV
5.60.458.39522+2+2+23613A14 PVT
5.40.397.7636N2+1+10311A15 PVT
7.90.6813.410652+2+1+45 / 3824317A16 PV
7.50.5710.97281+1+1+60 / 511868A17 PV
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A= complicated by erythromelalgia and/or migraine-like atypical transient ischemic attacks, B= asymptomatic ET or PV, ET= essential 
thrombocythemia, PV= polycythemia Vera, PVT=PV after phlebotomy
Table 6: Peripheral blood and bone marrow data in 14 ET and 16 PV patients observed between 1975 and 1981, University Hospital, 
Dijkzigt, Rotterdam [1]
Increase of clustered large pleomorphmegakaryocytes in bone marrow smears and biopsies was diagnostic for MPD in 14 ET and 
16 PV patients (Table 6) (Figures 1 and 2). A normocellular bone marrow picture (cellularity <60%) with increase of clustered 
pleomorphic megakaryocytes and no increase of cellularity (Figure 1) was seen in 7 of 14 ET and in one of 16 PV patients.
ErythrocHtHbPlateletsBMBMBMEry/PlasmLAFLeukocNumber
1012 /Lmmol/l109/LcellularitymegakarRFvolumescore109/L
7.10.6412.210351+2+1+63 / 5018414A18 PV
6.40.7013.313202+2+1+50 / 4021916A19 PV
7.60.6511.913001+2+1+38 / 5212818A20 PV
7.10.6112.110852+2+2+43 / 3717013A21 PV
7.50.5911.07082+2+1+42 / 3516817A22 PV
9.10.7213.19592+2+1+54 / 422199A23 PV
9.90.6612.56092+82 / 46 21518A24 PV
4.40.325.329752+2+2+38 / 36235B 1 PV
4.00.428.36992+1+28 / 58205B 2 ET
7.30.3811.39182+2+1+58 / 6214014B 3 PV
7.70.6312.725002+2+2+44 / 5114023B 4 PV
5.10.5010.0810N1+1+30 / 3811818B 5 ET
5.00.479.0737N1+1+28 / 371239B 6 ET
Figure 1: Presence of large platelets in peripheral (EDTA) blood smear (left top), increase of clustered enlarged megakaryocytes in 
a normocelluar ET bone marrow with stainable iron (left bottum). Local increase of erythropiesis (bold arrows) in areas of loose 
clustered pleomorphic megakaryocytes in patients with essential thrombocythemia: ET bone marrow picture [1]
A moderate increase of cellularity (1+ = 60-80%) in the bone marrow due to increased erythropoiesis leading to a ET/PV picture 
was seen in 3 ET and 4 PV patients (Figure 2). A typical PV bone marrow picture with pronounced increase of cellularity (2+ 
= 80-100%) due to predominantly increased erythropoiesis or trilinear hypercellular hematopoiesis due to erythro/megakaryo/
granulocytic myeloproliferation (EMGM) was seen in 2 of 14 ET patients and in 11 of 16 PV (Figure 2). These results indicate that 
bone marrow histopathology on its own is not reliable to differentiate between ET and PV but appeared to be a powerful tool to 
differentiate ET and PV from all variants of primary or secondary erythrocytosis and reactive thrombocytosis with a sensitivity 
and specificity near to 100%. The morphology of large pleomorphic megakarocyteswere not different in ET and PV. Pleomorphism 
of megakaryocytes became more pronounced in the hypercellular (80-100%) bone marrows of advanced PV (Figure 2).
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Figure 2: ET (left upper), ET/PV (left right), and PV (left bottum) bone marrow features in ET and PV patients. Pleiomorphic megakaryocytes 
in ET (upper panels) have less hyperlobulated nuclei as compared to PV (left bottum). Dense clustered pleiomorphic megakaryocytes in PV/
RF (right bottum) in advanced PV show dysmorphic nuclei [1]
RCP defined ET and PV patients show overlapping bone marrow pictures with increase of pleomorphic clustered megakaryocytes 
and varying degrees of increased erythropoisesis at time of diagnosis (Figures 1 and 2). The correlation curves between erythrocyte 
count, hemoglobin (Hb) or hematocrit (Ht) versus red cell mass (RCM) showed the best correlation between erythrocyte counts 
and RCM (Figure 3). Increased erythrocyte counts above 5.8x1012/L is diagnostic for PV (Table 1B) in the presence of large 
pleomorphic megakaryocytes in a bone marrow smears and biopsy. Increase of erythrocytes appears to be independent from the 
iron deficient status and persists in PV in a clinical remission obtained by repeated venesection (Figures 4 and 5). Two ET patients 
(A1 and A11, Table 6) had borderline increased RCM, which was associated with erythrocytes above 5.8x1012/L, increased LAP 
score, and a negative bone marrow iron stain. In retrospect both cases should be reclassified as PV patients. The ET case (A6) with 
an erythrocyte count of 6.0x1012/L and increased LAP score developed PV within 2 years. Bone marrow iron stain was negative in 
all PV patients (N=16) and in 4 out of 12 evaluable ET patients. 
Figure 3: Correlation of erythrocyte counts and erythrocyte volume or red cell mass in 5 ET and 13 PV patients. Two ET patients with borderline increased 
RCM had erythrocyte counts above 5.8x1012/L associated with a typical PV bone marrow histology and should in fact be diagnosed as PV. Erythrocyte count 
at a cut off level of 5.8x1012/L differentiates between ET and PV even in iron deficient state of PV remission after phlebotomy
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Figure 4: Case 2 in Table 7 with a 10 to 5 years history of stable JAK2V617F positive ET disease and ET bone marrow picture in 2006: normocellular ET 
stage 1 showing a typical ET bone marrow picture with cellularity of 60% due to slight increase of erythropiesis (upper panels). Case 6 in Table 7 with 
ET and a PV bone marrow in 1997, who developed PV seven years later in 2004 with a good response to interferon in 2005 (lower panels)
Figure 5: Case 7 in Table 7 presented with rapid onset JAK2V617F positive erythrocythemic PV with a typical PV bone marrow picture in 2005 
carrying homozygous JAK2V617F mutation on repeated testing. The erythrocyte counts were far above 6x1012/L and remained above 6x1012/L at 
time of hematological remission of PV for several years by phlebotomy alone on top of low dose aspirin
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Table 7A: Clinical features of 6 ET, and 4 patients carrying the JAK2V617F mutation
Results period 1997→2007
Between 1997 and 2007 we prospectively studied 10 JAK2V617F mutated patients, who presented with erythromelalgia or migraine-
like microvascular cerebral ischemic attacks (MIA) and were referred for expert evaluation and treatment recommendation (Table 
7). The clinical diagnoses were ET in 6 and PV in 4 without the use of bone marrow histopathology (Table 7A). The 6 ET were 
heterozygous for the JAK2V617F mutation. Three PV patients were homozygous for the JAK2V617F mutation (Case 7, 9 and 10, Table 
10 in Table 7). All ET patients had an erythrocyte count below 5.8x1012/L and all PV had erythrocyte counts above 6x1012/L 
(Figures 4, 5 and 6) (Table 7A).
10987654321Case
38/M47/F43/F50/M31/F40/F47/F66/F60/M56/MAge, years. F /M
384924405397576425553544814575Platelets x109/L
+++++/-+++/-+/-+/-+/-+/-+/-JAK2V617F
zerozerode-creasedzerodecreased.nt.
decre-
asd.decreasedzeroNormalSerum EPO
8.013.114.37.36.26.18.212.95.36.7Leukocytes x109/l
284232263163186NN1971609ntLAP score (N=<100)
12.816.317.318.614.013.414.414.215.513.6Hemoglobin g/dl
0.600.530.520.630.410.400.440.440.450.40Hematocrit
6.77.46.16.3.4.94.64.84.75.34.5Erythrocytes x1012/L
+++++.nt.nt.+++EEC
↑↑↑↑N.nt.NNNNRed cell mass
1614.31313.711.816.5131613.Spleen, echogram cm
PVPVPVPV ETETETETETETClinical diagno-sisNo use of BM
Figure 6: Rapid onset trilinear JAK2V617F homozygous positive PV Case 9 in Table 7 with a typical trilinear PV bone marrow picture complicated by bleeding, 
poor response to pegylated interferon indicating the need to treat with hydroxyurea on top of low dose aspirin resulting in eliminating the thrombo-hemorrhagic 
diathesis and significant imporovement of quality of life during long-term follow-up (2006-2013) 
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10987654321Case
80%80%65%80%75%80%75%90%65%60%Cellularity
-1.510,70,740,5111M:E ratio
↑↑NNN↑N↑N   N  Myeloid lineage
↑↑↑↑↑N↑↑↑↑Erythroid lineage
MF-0MF-1MF-0MF-0MF-0MF-0MF-0MF-0MF-1MF-0Myelofibrosis: MF
PVPVPVPVETMPNucETETETETDiagnosis 2008 WHO
PVPVPVPVPVEMGMPVPVETETBone marrow diagn
PVPVPVPVPro-PVEMGMPro-PVPro-PVET1 ET1Diagnosis2008 ECMP
1 yr5 yrs1 yr4 yrs8 yrs15 yrs11 yrs10 yrs12 yrs4 yrsFollow-up up to 2008
Phleb/HUPhleb/HUPhlebPhlebHigh IFNnoHULow IFNaspirinaspirinTreatment 2008
PVPVPVPVPVEMGMPVRemissionETETDiagnosis in 2012
HUHUPhlebPhlebPhebnoHUVery low IFNaspirinaspirinTreatment 2015
Table 7B: Bone marrow features of 10 JAK2V617F mutated thrombocythemia patients with the clinical diagnosis of ET in 6 and PV in 4 cases
The clinical diagnosis of the 10 JAK2V617F positive patients without the use of bone marrow histology data was ET in 6 and PV in 4 
cases (Figures 4, 5 and 6) (Table 7A).
The diagnosis of the 10 JAK2V617F positive MPN patients based on bone marrow histology picture alone as blindly judged by 
pathologists and was consistent with ET in 3 and PV in 7 cases (Table 7B). The 3 ET patients diagnosed as PV bone marrow 
histology evaluation had very low serum EPO levels and EEC, but erythrocyte counts less than 5.8x1012/L consistent with the 
diagnosis of prodromal PV (Table 7B).
The diagnoses according to 2008 WHO criteria were ET in 5, MPN unclassifiable in 1 and PV in 4. The diagnoses according to 
the WHO-ECMP criteria for diagnosis and staging of ET and PV patients (Tables 2 and 3) were normocellular ET in 2 cases, 
prodromal PV (ET with low serum EPO, the presence of EEC and normal erythrocyte counts) in 3 cases, ET with a MGM bone 
marrow histopathology (ET.MGM Table 7B) with no leuko-erythroblastosis in 1 case, and acute onset PV in 4 patients (Cases 7, 8, 
9 and 10, Table 7B). Examples of bone marrow histopathology of normocellular ET and prodromal PV are shown in figure 4 and 
of PV in figure 6 demonstrating that bone marrow histopathology alone cannot distinguish JAK2V617F mutated ET, prodromal PV 
and PV. 
Bone marrow cellularity of the 10 JAK2V617F mutated MPN patients (6 ET and 4 PV) ranged from range 60% to 90% (Table 7B).
There was an increased erythropoiesis in 8/10 and increased granulopoiesis in 4/10 patients. Interestingly, 3 ET with early features 
of PV (prodromal PV) fulfilled the bone marrow features of prodromal PV and 4 cases presented with rapid onset PV (Cases 7, 8, 
9 and 10). The three ET patients with prodromal PV developed overt PV after long-term follow-up of 8, 9 and more than 10 years 
(slow onset PV, Table 7). Myelofibrosis (MF) was scored according to Table 1 Case MF-0 (RF-0/1) in 8 (5 ET, 3 PV), and MF-1 
(RF-2) in 2 (1 ET, 1 PV) MPN patients. ET case 5 showed increased megakaryocytic-granulocytic myeloproliferation (MGM) bone 
marrow histology consistent with the ET.MGM-entity (Table 7B).
Results period 2008→2012
JAK2 wild type ET carrying the MPL515 mutation: In 2008 we studied bone marrow histopathology in 12 cases with JAK2 wild 
type ET carrying the MPL515 mutation kindly provided by the courtesy of Dr. Vannucchi, Florence, Italy. Bone marrow histology 
from a recent patient with JAK2 wild type ET carrying the MPL515 mutation consistently displayed clusters small and large 
megakaryocytes with a greater number of giant megakaryocytes with hyperlobulated stag-horn nuclei in a normal cellular bone 
marrow and no increase of erythropoiesis as compared to JAK2V617F ET with features of PV in the bone marrow (Figure 7). Bone 
marrow histopathology in MPL515 mutated ET (Figures 8, 9 and 10) versus WHO-ECMP defined JAK2V617F mutated ET were 
different on 4 points. 
First, The presence of clustered small and giant megakaryocytes with deeply lobulated stag-horn like nuclei (Figures 7, 8 and 
9) in ET carrying the MPL515 mutation are not seen in JAK2V617F positive ET, prodromal PV, ET.MGM and PV. The pleomorphic 
megakaryocytes in JAK2V617F mutated ET in bone marrow smears and bone marrow biopsy were not larger but similar in size with 
small, medium and large megakaryocytes (pleomorphic) as in PV (Figure 4 and 6).
Second, there was local increase of erythropoiesis in areas of loose clustered pleiomorphicmegakaryoctyes in JAK2V617F mutated 
normocelluar ET and in prodromal PV (Figure 7).
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Figure 7: 65 years old man with RBC 5.37x1012L, HB 15.8 g/dL, MCV 89, WBC 12.0 x10/9/L, Plts 517x109L, LDH 600 UI/L 
and JAK2V617F mutation (allele burden: 20% on peripheral blood). Diagnosis PV according WHO-ECMP (left). 55 years old 
woman with MPL515-positive normocellular ET with normal values for hemoglobin, hematocrit, leukocytes and platelet around 
1000x109/L. Dr. Campr: small medium, large and giant megakaryocytes with staghorn-like hyperlobulated nuclei (right)
Figure 8: JAK2 wild type ET carrying the MPL515 mutation with enlarged and giant mature megakaryocytes with loose clusters of 
hyperlobulated, “stag-horn” hyperlobulated nuclei. Case 1 and 2, Dr. Vannucchi, upper panels. Case 3, Dr. Vannucchi lower panels
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Figure 9: JAK2 wild type, MPL515 mutated ET with enlarged and giant mature megakaryocytes with loose clusters of hyperlobulated, “stag-
horn” hyperlobulated nuclei. Case 4, Dr. Vannucchi, upper panels. Case 5, Dr. Vannucchi, lower panels
Third, JAK2 wild type ET carrying the MPL515 mutation have no clinical, laboratory and bone marrow features of prodromal PV at 
diagnosis, do not evolve into overt PV during follow-up, and have normal serum EPO and ferritin levels. 
Fourth, we observed significant increased reticulin fibrosis grade 2 to 3 in MPL515 mutated ET in bone marrow areas of 
normocellularity but with dense clustered megakaryocytes (Figure 10), which is not seen in JAK2V617F mutated normocellular ET, 
hypercellular prodromal and PV (Figure 10). 
Figure 10: Case of JAK2 wild type MPL515 mutated ET with clustered large and giant megakaryocytes and increase of reticulin fibrosis grade 
2 (RF 2). Such increase of RF 2 in a normocellular bone marrow is not seen in JAK2V617F mutated ET and PV, and also not in JAK2 wild type 
PMGM(Figures 11 and 12) and CALR-MGM (Figures 13 and 14)
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Result 2014 → 2015
JAK2-MPL-wild type CALR mutated PMGM: From 1994 to 2006, we documented a case of JAK2 wild type ET with a PMGM 
bone marrow (Figure 11) in a 9-year-old boy (referred to us from Basel, Switserland) with a platelet count of 1596 to 1946x109/l, 
no splenomegaly on palpation, white blood differential count metamyelocytes 0.5%, banded forms 1%, segmented granulocytes 
52%, basophiles 2.5%, lymphocytes 35% monocytes 6%, low LAP score, and a hypercellular (80-100%) bone marrow with a 
predominant prefibrotic primary megakaryocytic and granulocytic myeloproliferation (PMGM, Table 5), absence of reticulin fibers, 
loose to dense clustering of large dysmorphic megakaryocytes variable in size with cloud-like hypoploid nuclei. The dysmorphic 
megakaryocytes show definite abnormalities of maturation with bulky (bulbous) hyperchromatic nuclei and some disturbances 
of the nuclear cytoplasmic ratio (Figure 11, arrows), which are not seen in JAK2 wild type ET carrying the MPL515 mutation and 
also not in prefibrotic JAK2V617F mutated ET, prodromal PV and PV. Such bone marrow findings of PMGM are consistent with 
pronounced ET as the presenting feature of prefibrotic PMGM, and do not meet the criteria for fibrotic PMF according to the 2008 
WHO classification (Table 5) [15,18]. The 10 years follow-up from 1994 to 2004 showed normal blood cells counts, absence of the 
JAK2V617F mutation, no evidence of myelofibrosis, and no splenomegaly on palpation (Figure 11).
Figure 11: Third MPN entity presenting with JAK2 wild type ET associated with prefibrotic primary megakaryocytic and granulocytic 
myeloproliferation (PMGM, colour picture), which is characterized by a hypercellular bone marrow due to dual myeloproliferation of granulopoiesis 
and dense clustered enlarged immature dysmorphic megakaryocytes with bulky (bulbous) hyperchromatic nuclei (arrows), which are never seen in 
JAK2 wild type MPL515 mutated ET and also not in the prefibrotic JAK2V617F mutated ET. During long-term follow-up, reduction of platelet count 
to normal or near normal by treatment with hydroxyurea in 1994 followed by anagrelide from 1995 to 1998 the bleeding manifestations did not 
recur. After discontinuation of anagrelide in 1998 the patient remained asymptomatic, the platelet counts were between 600 and 800x109/L, which 
normalized after 8 years of follow-up. From 2001 to 2005 haemoglobin and hematocrit reached completely normal values
Bone marrow histology in CALR mutated JAK2 wild type ET and MF: We prospectively observed in 2004 a case of WHO-
ECMP defined PMGM (Table 5) (Figure 12) in a 37-years old woman (asymptomatic except fatigue) with JAK2 wild type (anno 
2006) hypercellular ET: platelets 1205 x109/L, Hemoglobin 12.5 g/dl, leukocytes 18 x109/L, borderline LDH, spleen size 13 cm on 
echogram (normal value <12cm) as the presenting features of primary megakaryocytic granulocytic myeloproiferation (PMGM, 
RF-1, Figure 12). This early fibrotic stage of JAK2 wild type hypercellular ET associated with PMGM developed anemia, significant 
splenomegaly and myelofibrosis during 10 years of follow-up and appeared to be CALR positive when tested in 2014. 
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In 2014/2015 we prospectively studied seven consecutive newly diagnosed CALR positive hypercellular ET or MF and found 
consistent bone marrow characteristics of hypercellular thrombocythemia as the presenting feature of prefibrotic and early fibrotic 
stages of JAK2 wild type PMGM. Four of these seven CALR mutated MPN patients presented with aspirin sensitive microvascular 
disturbances of erythromelalgic, cerebral and ocular ischemic manifestations (Sticky Platelet Syndrome) as the specific presenting 
manifestations of myeloproliferative thrombocythemia. Bone marrow histology in prefibrotic cases of CALR ET (Figure 13 left), 
and in early fibrotic stage CALR MF (Figure 13 right) show dysmorphic megakaryocytes with definite abnormalities of maturation 
with bulky (bulbous) hyperchromatic nuclei and some disturbances of the nuclear cytoplasmic ratio consistent with CALR mutated 
PMGM, which are not seen in MPL515 mutated ET and also not in JAK2V617F mutated ET, prodromal PV and classical PV. 
Figure 12: 37-years old woman (asymptomatic except fatigue) with JAK2 wild type hypercellular ET (anno 2006): platelets 1205 
x109/L, Hb 12.5 g/dl, leukocytes 18 x109/L, borderline LDH, spleen size 13 cm on echogram (normal value <12cm) as the presenting 
features of primary megakaryocytic granulocytic myeloproiferation (PMGM, RF-1) diagnosed according ECMP criteria but not 
meeting the 2008 WHO criteria for primary myelofibrosis (PMF). In 2015 this case proved to be calcireticulin (CALR) mutated
Recently, we observed a case of aleukemic splenomegaly in a 67 year-old-man, who presented in January 2015 with anemia with 
normocytic anemia (hemoglobin 5.2 mol/l, hematocrit 0.25 and erythrocytes 3.1x1012/L, platelets 265x109/L, leukocytes 6.5x109/L) 
weight loss from 84 to 71 kg in the last 2 years, minor fatigue, no sweatings and asymptomatic splenomegaly on physical examination 
(Figure 14). The spleen length on echogram was 24 cm. Morphology of periperal blood smear showed anisoctytosis, trear drop 
erythrocytes and spherocytes, white blood cell differential counts was normal with the presence of banded (2-4%), blasts (1-2%), 
myelocytes (2-5%) and erythroblasts (3-4% of WBC). There was a drytap on bone marrow aspiration. Bone marrow biopsy revealed 
a strongly fibrosed hematopietic stroma with numerous dysmorphic dense clustered dysmorphic megakaryocytes, with remnants 
of previous erythropietic and myeloid precursor cells and reticulin fibrosis grade 3 to 4 (Figure 14), which could be diagnosed as 
JAK2 wild type calreticulin (CALR) mutated MF without a history of ET. This CALR mutated MF must have had a long history 
of subclinical CALR MPN as Michiels & Ten Kate already have demonstated in the 1980s (Table 8) [17]. In 1992, we analysed the 
long-term follow-up of a 61-year-old man, who presented in 1971 with primary myeloid metaplasia of the spleen initially diagnosed 
as prefibrotic primary myeloproliferative disease (MPD) upon bone marrow histology (Table 8) [17]. The spleen size increased 
from 18 cm to 23 cm length diameter on scan (normal value <12cm) in 1978 and 1988, but the peripheral blood counts remained 
normal for 14 years of follow-up (Table 8). From 1985 to 1989 he suffered from aspirin responsive erythromelalgia of fingers and 
toes at platelet counts of 421x109/L. After 17 years of follow-up this case of PMD developed in 1988 anemia, thrombocythemia, 
and symptoms related to splenomegaly consistent with the diagnosis of agnogenic myeloid metaplasia and advanced myelofibrosis 
(MF 2/3). 
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Figure 13: Bone marrow features in newly diagnosed calreticulin (CALR) mutated essential thrombocythemia (ET, left) and early 
stage myelofibrosis (MF, right)
Left: Clinical case of JAK2/MPL negative and calcireticulin (CALR) positive ET who presented with normal vlaues for hemogobin, 
hematocrit and erythrocytes, platelet count of 1832x109/L and slight splenomegaly (16 cm lenght diameter on echogram). Bone marrow 
histology is hypercellular with relative decrease of erythropoisis, dense cluster of immature megakaryocytes with hypolobulated nuclei 
consistent typical PMGM and no increase of reticulin fibrosis (Table 5) 
Right: Clinical case of CALR positive myelofibrosis (MF): hemoglobin 11.2 g/dL,hematocrit 0.33, leukocytes 9.2x109/L, platelets 
347x109/L, LDH 1393 U/l, and the presence of tear drop erythrocytes, poikolocytosis and polychromasie in a peripheral blood smear, 
and hypercellular bone marrow with relative decrease of erythropoisis, dense cluster of immature megakaryocytes with hypolobulated 
nuclei consistent with PMGM, and reticulin fibrosis (RF) grade 2.The marrow histology features similar to WHO-defined primary 
myelofibrosis (PMF) and WHO-ECMP-defined PMGM or CALR-MGM, but distinct from JAK2V617F mutated ET and PV, and distinct 
from MPL515 mutated ET
Figure 14: A 67 year old man presented in 2015 with normocytic anemia (hemoglobin 5.2 mol/l, hematocrit 0.25 and erythrocytes 
3.1x10 12/L, platelets 265x109/L, leukocytes 6.5x109/L) weight loss from 84 to 71 kg in the last 2 years, minor fatigue, no sweatings, 
asymptomatic splenomegaly and dense clustered dysmorphic megakaryocytes, reticulin fibrosis grade 3 to 4, which was diagnosed as 
JAK2 wild type calcireticulin (CALR) mutated MF without a history of ET
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Discussion
In 1940, Dameshek believed that the following minimal data should be present before a definite diagnosis of PV can be made: 
plethoric appearance, splenomegaly, definitely elevated erythrocyte count above 6x1012/L, elevated platelet count, and elevated 
hematocrit (Table 1) [18]. The bone marrow is diagnostic showing increased trilinear hematopoiesis and large megakaryocytes. 
ET and PV patients present identical (typical) ET/PV or PV bone marrow histology pictures and the most objective criterion to 
differentiate ET from PV appeared to be the erythrocyte count at a cutoff level of 5.8x10/12L obviating the need to measure red cell 
mass (RCM) (Tables 2 and 3) (Figures 3 and 5). We did not observe a significant difference in the morphology of pleomorphic 
megakaryocytes within the prefibrotic JAK2V617F mutated MPNs normocellular ET, prodromal PV and PV. In JAK2V617F positive 
EMGM (or masked PV), the pleomorphic megakaryocytes show dysmorphic features of nuclei (not cloud-like), which is clearly 
in between ET and post-ET myelofibrosis (Table 2). There is significant overlap of serum EPO levels in PV versus control and 
controls versus increased serum EPO in congenital erythrocytoses [11-13]. A low serum EPO level has been described in about 
half of PVSG defined ET patients, who are predicted to carry the JAK2V617F mutation and can be regarded as prodromal (forme 
frusta) PV [11,12]. The diagnostic impact of low serum EPO (ELISA assay) below the normal range (<3.3IU/L) had a sensitivity, 
specificity and positive predictive value of 86%, 97% respectively for the diagnosis of PV [13]. Piche, et al described the bone marrow 
histopathology findings in 59 JAK2V617F positive ET and 44 JAK2 wild ET cases [16], which are completely in line with the present 
study that ET patients with JAK2V617F mutation indeed have PV-like morphological bone marrow changes of pleomorphic large 
megakaryocytes. Our findings in WHO-ECMP defined ET, prodromal PV patients and PV patients with increased erythrocytic, 
megakaryocytic and granulocytic myeloroliferation (JAK2V617F-EMGM) as well as increased serum LDH levels and spleen size were 
seen in more pronounced cases JAK2V617F positive ET in particular at higher JAK2V617F mutation load [16]. 
1989a19891988198519781971
-+++--Erythromelalgia
Peripheral blood
5.85.75.97.18.09.8Hemoglobin mmol/l
223811484421265285Platelets X109/l
182421.921.410.86.9LeukocytesX109/l
Bone Marrow
↑↑↑NCellularity
NNNNErythropoiesis
----Ringed sideroblasts
↑↑↑↑↑↑Megakaryocytes
↑↑↑↑↑↑↑↑↑Reticulum
↑↑↑--Collagen
+---Osteoid  
----Myelodysplasia
Karyotype of bone marrow cells
Spleen size on scan
2318Length diameter cm
*N, normal ; ↓,decreased; ↑, increased; -, absent; +, present. One arrow slight, two arrows pronounced, and three exceptional. The 
peripheral blood and bone marrow findings are consistent with agnogenic myeloid metaplasia in case 1.a While on treatment with 
Hydroxyurea
Source Michiels and Ten Kate, Amer J Hematol 1992; 39: 131-136 [17]
Table 8: Hematological Findings in Cases of Erythromelalgia and Atypical Thrombocythemia*
Our bone marrow findings of JAK2 wild type ET patients carrying the MPL515 mutation displayed small and giant megakaryocytes 
with a greater number of large deeply lobulated stag-horn nuclei and more dense clustered megakaryocytes in a normocellular 
bone marrow with no increase of erythropoiesis. JAK2 wild type MPL515 mutated ET has no clinical, laboratory and bone marrow 
features of prodromal PV at diagnosis and does not evolve into overt PV during follow-up [19-21]. JAK2 wild types ET carrying 
the MPL515 mutation have normal serum EPO and ferritin levels and no spontaneous endogenous erythroid colonies (EEC). The 
prevalence of ET or MF patients carrying the MPL515 mutation may range from 5 to 10% of the JAK2 wild type MPN population. In 
a large collaborative European study, Jones, et al. [21] investigated a cohort of 176 MPN cases with the MPL515 mutation: W515L in 
110 and W515K in 58. The overall mutation levels were lower (25%) in W515L (N=106) than the level of 37% in cases with W515K 
(N = 32). Of the 138 cases (ET, N = 99; MF, N = 36), the median W515L mutation levels were significantly lower (21%) in ET than 
those (46%) in MF. The 29 homozygous MPL515 positive cases had a diagnosis of MF in 15 and ET in 12 patients. 
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JAK2 wild type prefibrotic primary megakaryocytic granulocytic myeloproliferation (PMGM) according to the 1990 Hannover 
Bone Marrow Classification [22-24] has been labeled as prefibrotic primary myelofibrosis (PMF) in the 2008 WHO classification 
[10] and represent the third distinct MPN entitiy [22]. In this report, JAK2/MPL wild type, hypercellular ET is associated with a 
PMGM bone marrow (Table 5) (Figures 11, 12 and 13). The bone marrow findings in CALR mutated ET and MF in Figures 13 and 
14 are consistent with WHO defined prefibrotic PMF and with WHO-ECMP defined PMGM (Table 5). The bone marrow features 
in CALR-MGM in two cases with hypercellular ET in Figure 13 clearly differs from the pleomorphic megakaryocytes in JAK2V617F 
mutated ET and PV and from giant megakaryocytes and hyperlobulated staghorn-like nuclei in MPL515 mutated ET [25]. The 
updated 2015 WHO-ECMP criteria in Tables 2, 3, 4 and 5 have the potential to properly diagnose and stage the each of the JAK2V617F, 
JAK exon 12, MPL515 and CALR mutated MPNs based on clinical features (splenomegaly, LDH, degree of anemia), relevant bone 
marrow histology criteria, grading of bone marrow fibrosis, constitutional symptoms and laboratory features including EEC, EPO 
levels, and mutation load (Figure 15) [15,25]. The broad spectrum and its various clinical evolution patterns in terms of primary 
hematopoietic neoplasms of the spleen and secondary fibrosis of the bone marrow in JAK2V617F, MPL515- and CALR-mutated MPN 
has to be further delineated in prospective clinical and basic research studies.
Normocellular ET  
JAK2 V617F+  
PV JAK2 V617F+/++  
exon12+ 
 
 
Normocellular ET 
JAK2 wild type 
MPL 515 
 
Post-PV MF 
Post-ET MF 
JAK2 V617F ++ 
 
ET.MGM  
Masked PV 
JAK2 V617F++ 
Prodromal PV 
JAK2 V617F+ 
 
Réticuline fibrosis 
RF-1, 2, 3, RCF 
 
CALR PMGM 
Hypercellular ET 
JAK2 wild type 
MF 
RF 1, 2, 3 RCF 
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Acute onset PV 
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Figure 15: 2015 WHO-ECMP Myeloproliferative Neoplasms Classification and Transitional states
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